journal article·2026-05-06Open access

Engineering Liposomes and Polymer Conjugates: A Platform for Mechanistic Complement Activation Studies and Controlled Release Applications

Kilian Hoecherl, Johannes Konrad, Christina Reiner, Simon Streif, Clemens Spitzenberg, Carola Sommer, Diana Pauly, Miriam Breunig, Antje J. Baeumner

ACS Applied Materials & Interfaces· Volume 18· Issue 17

Abstract

Due to their ability to encapsulate both hydrophilic and hydrophobic molecules and to allow for their controlled release, liposomes have evolved into a promising and frequently used tool in medicine, biotechnology, and bioanalysis. In this work, we designed liposome surfaces and polymer conjugates to reliably and in a controlled fashion activate the complement system and monitor its function. Specifically, the polymer conjugates were designed on protein, polysaccharide, or synthetic polymer backbones, respectively, enabling flexible coupling chemistry and size tuning. They were optimized as trigger entities for efficient stimulation of complement responses through specific surface interactions with the liposome membrane and complement proteins simultaneously. Additionally, the liposome surface chemistry was optimized to ensure the specificity of the binding and complement stimulation. Studies with human serum confirmed the applicability of the new assay principle providing in-depth understanding of complement action. Specifically, increasing the density of trigger moieties enhanced the complement activation efficiency. Complement lysis strongly relies on the physiological geometry of trigger and recognition sites and correlates with cross-linking of liposomes. Since the liposomes demonstrated high long-term stability and the trigger entities offered a range of polymer backbones, this new principle is a platform technology that will be applicable for a broad spectrum of assays, including immunoassays, in-depth investigations of complement activation and regulation, and targeted release of liposome encapsulants for drug delivery systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Complement system in diseases · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Analytical Chemistry, Chemo- and Biosensors, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany

Department of Pharmaceutical Technology, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany

Experimental Ophthalmology, University of Marburg, Baldingerstraße, 35043 Marburg, Germany

Funding

Bundesministerium f?r Forschung, Technologie und Raumfahrt (BMFTR)

References (77)

Show source-provided references
1. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
2. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
3. 10.5114/bta/20768010.5114/bta/207680 ↗
4. 10.1080/08982104.2024.234113910.1080/08982104.2024.2341139 ↗
5. 10.1080/17458080.2016.114827310.1080/17458080.2016.1148273 ↗
6. 10.1016/j.talanta.2005.08.04410.1016/j.talanta.2005.08.044 ↗
7. 10.1021/acs.analchem.5c0252610.1021/acs.analchem.5c02526 ↗
8. 10.3390/molecules2704137210.3390/molecules27041372 ↗
9. 10.1211/jpp.59.4.000110.1211/jpp.59.4.0001 ↗
10. 10.2147/IJN.S4929710.2147/IJN.S49297 ↗
11. 10.1002/jps.2198810.1002/jps.21988 ↗
12. 10.1080/17425247.2022.209983410.1080/17425247.2022.2099834 ↗
13. 10.1002/wnan.145010.1002/wnan.1450 ↗
14. 10.3389/fphar.2019.0165010.3389/fphar.2019.01650 ↗
15. 10.1038/nmat377610.1038/nmat3776 ↗
16. 10.1021/acscentsci.8b0028610.1021/acscentsci.8b00286 ↗
17. 10.1073/pnas.131458511010.1073/pnas.1314585110 ↗
18. 10.1046/j.1365-2958.1999.01435.x10.1046/j.1365-2958.1999.01435.x ↗
19. 10.3390/pharmaceutics1702024510.3390/pharmaceutics17020245 ↗
20. 10.1016/j.jconrel.2022.08.00110.1016/j.jconrel.2022.08.001 ↗
21. 10.12688/f1000research.10065.110.12688/f1000research.10065.1 ↗
22. 10.3389/fimmu.2015.0026210.3389/fimmu.2015.00262 ↗
23. 10.1038/s41467-019-10058-710.1038/s41467-019-10058-7 ↗
24. 10.1073/pnas.79.23.747410.1073/pnas.79.23.7474 ↗
25. 10.1073/pnas.190184111610.1073/pnas.1901841116 ↗
26. 10.1021/bi500157z10.1021/bi500157z ↗
27. 10.3389/fimmu.2015.0025710.3389/fimmu.2015.00257 ↗
28. 10.1016/j.smim.2024.10192110.1016/j.smim.2024.101921 ↗
29. 10.1016/j.ejpb.2023.10.00810.1016/j.ejpb.2023.10.008 ↗
30. 10.1124/pharmrev.120.00007210.1124/pharmrev.120.000072 ↗
31. 10.1172/JCI9096210.1172/JCI90962 ↗
32. 10.1016/j.jaut.2022.10297910.1016/j.jaut.2022.102979 ↗
33. 10.1007/s00216-025-05882-410.1007/s00216-025-05882-4 ↗
34. 10.1021/acs.analchem.5c0450610.1021/acs.analchem.5c04506 ↗
35. 10.1007/s15010-020-01503-710.1007/s15010-020-01503-7 ↗
36. 10.3109/1071754950903135710.3109/10717549509031357 ↗
37. 10.1016/j.ijpharm.2013.06.03110.1016/j.ijpharm.2013.06.031 ↗
38. 10.1166/jbn.2014.179210.1166/jbn.2014.1792 ↗
39. 10.1016/0014-5793(91)80216-P10.1016/0014-5793(91)80216-P ↗
40. 10.1006/abio.1996.038410.1006/abio.1996.0384 ↗
41. 10.1016/0003-2697(92)90022-Y10.1016/0003-2697(92)90022-Y ↗
42. 10.1126/science.124894310.1126/science.1248943 ↗
43. Hughes-Jones N. C. · Immunology · 1977 · 32 · 191
44. 10.1016/S0021-9258(19)44080-510.1016/S0021-9258(19)44080-5 ↗
45. 10.1080/14686996.2019.162717410.1080/14686996.2019.1627174 ↗
46. 10.1016/j.jconrel.2015.06.02310.1016/j.jconrel.2015.06.023 ↗
47. 10.1016/j.jconrel.2021.11.04210.1016/j.jconrel.2021.11.042 ↗
48. 10.1039/D1TB01485D10.1039/D1TB01485D ↗
49. 10.1016/0005-2736(94)90231-310.1016/0005-2736(94)90231-3 ↗
50. 10.1023/A:101896512122210.1023/A:1018965121222 ↗
51. 10.1016/0005-2736(95)00005-N10.1016/0005-2736(95)00005-N ↗
52. 10.1016/j.addr.2011.06.01710.1016/j.addr.2011.06.017 ↗
53. 10.1016/j.nano.2011.06.00310.1016/j.nano.2011.06.003 ↗
54. 10.1016/j.ijpharm.2024.12413110.1016/j.ijpharm.2024.124131 ↗
55. 10.1295/polymj.19.47510.1295/polymj.19.475 ↗
56. 10.1007/s00216-008-1992-110.1007/s00216-008-1992-1 ↗
57. 10.1021/ac010588810.1021/ac0105888 ↗
58. 10.1021/acs.langmuir.6b0259110.1021/acs.langmuir.6b02591 ↗
59. 10.1007/s00216-021-03750-510.1007/s00216-021-03750-5 ↗
60. 10.1039/C5CS00048C10.1039/C5CS00048C ↗
61. 10.1248/bpb.32.52310.1248/bpb.32.523 ↗
62. 10.1016/0922-338X(89)90093-710.1016/0922-338X(89)90093-7 ↗
63. 10.1093/clinchem/41.4.58610.1093/clinchem/41.4.586 ↗
64. Complement Activity (CH50): The Wako Autokit CH50 is an in vitro liposome immunoassay (LIA) for the quantitative determination of total complement activity (CH50) in human serum using an automated procedure. https://healthcaresolutions-us.fujifilm.com/products/in-vitro-diagnostics/clinical-diagnostic-reagents/complement-activity-ch-50/. Accessed 29 Oct 2025.
65. 10.1128/CDLI.6.1.137-139.199910.1128/CDLI.6.1.137-139.1999 ↗
66. 10.1126/science.aao498810.1126/science.aao4988 ↗
67. 10.1016/j.carbpol.2011.12.01210.1016/j.carbpol.2011.12.012 ↗
68. Teraoka I. · 200210.1002/0471224510 ↗
69. 10.4049/jimmunol.160147310.4049/jimmunol.1601473 ↗
70. 10.1073/pnas.130489411010.1073/pnas.1304894110 ↗
71. 10.1016/S0006-3495(95)80369-310.1016/S0006-3495(95)80369-3 ↗
72. Flory P. J. · 1989
73. 10.1002/1438-5171(200006)1:2<123:AID-SIMO123>3.0.CO;2-310.1002/1438-5171(200006)1:2<123:AID-SIMO123>3.0.CO;2-3 ↗
74. 10.1021/ma101070s10.1021/ma101070s ↗
75. 10.1016/j.addr.2011.06.00210.1016/j.addr.2011.06.002 ↗
76. 10.1016/j.addr.2020.04.01210.1016/j.addr.2020.04.012 ↗
77. 10.3390/pharmaceutics1412257510.3390/pharmaceutics14122575 ↗